Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms

References

• McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121(7):722–730. doi:10.1161/CIRCRESAHA.117.309711
   PubMed Web of Science ®Google Scholar
• Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–1816.
   PubMed Web of Science ®Google Scholar
• Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971;172(3988):1150–1151. doi:10.1126/science.172.3988.1150
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 2012;126(10):1286–1300. doi:10.1161/CIRCULATIONAHA.111.078915
   PubMed Web of Science ®Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–172. doi:10.1016/j.jacc.2016.03.596
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492–1495. doi:10.3324/haematol.2013.094482
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689
   PubMed Web of Science ®Google Scholar
• Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163–178. doi:10.1007/s10741-014-9462-7
   PubMed Web of Science ®Google Scholar
• Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459–2462. doi:10.1126/science.1062245
   PubMed Web of Science ®Google Scholar
• Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1–25. doi:10.1007/s40120-016-0040-x
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. doi:10.1093/eurheartj/ehv338
   PubMed Web of Science ®Google Scholar
• Oghina S, Bougouin W, Bézard M, et al. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC Heart Fail. 2021;9(3):169–178. doi:10.1016/j.jchf.2020.12.005
   PubMedGoogle Scholar
• Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887. doi:10.1093/eurheartj/ehx350
   PubMed Web of Science ®Google Scholar
• Kristen AV, Schnabel PA, Winter B, et al. High prevalence of amyloid in 150 surgically removed heart valves–a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol off J Soc Cardiovasc Pathol. 2010;19(4):228–235. doi:10.1016/j.carpath.2009.04.005
   PubMed Web of Science ®Google Scholar
• Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826–1834. doi:10.1093/eurheartj/ehv583
   PubMed Web of Science ®Google Scholar
• Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020;300:191–195. doi:10.1016/j.ijcard.2019.07.051
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi:10.1093/eurheartj/ehx589
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–328. doi:10.1002/ajh.20381
   PubMed Web of Science ®Google Scholar
• Nijst P, Tang WW. Recent advances in the diagnosis and management of amyloid cardiomyopathy. Fac Rev. 2021;10:31. doi:10.12703/r/10-31
   PubMedGoogle Scholar
• Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol off J U S Can Acad Pathol Inc. 2015;28(2):201–207.
   PubMed Web of Science ®Google Scholar
• Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10–21. doi:10.1016/j.tcm.2017.07.004
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–481. doi:10.1016/j.ijcard.2016.04.030
   PubMed Web of Science ®Google Scholar
• Cacciapuoti F. The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis. J Echocardiogr. 2015;13(3):84–89. doi:10.1007/s12574-015-0249-1
   PubMedGoogle Scholar
• Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–540. doi:10.1016/j.acvd.2013.06.051
   PubMed Web of Science ®Google Scholar
• Rubinshtein R, Glockner JF, Feng D, et al. Comparison of magnetic resonance imaging versus Doppler echocardiography for the evaluation of left ventricular diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2009;103(5):718–723. doi:10.1016/j.amjcard.2008.10.039
   PubMed Web of Science ®Google Scholar
• Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981;63(1):188–196. doi:10.1161/01.CIR.63.1.188
   PubMed Web of Science ®Google Scholar
• Picano E, Pinamonti B, Ferdeghini EM, et al. Two-dimensional echocardiography in myocardial amyloidosis. Echocardiogr Mt Kisco N. 1991;8(2):253–259. doi:10.1111/j.1540-8175.1991.tb01395.x
   PubMed Web of Science ®Google Scholar
• Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–2110. doi:10.1016/j.jacc.2007.08.028
   PubMed Web of Science ®Google Scholar
• Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16(5):1135–1141. doi:10.1016/0735-1097(90)90545-Z
   PubMed Web of Science ®Google Scholar
• Swanton RH, Brooksby IA, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM. Systolic and diastolic ventricular function in cardiac amyloidosis. Studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol. 1977;39(5):658–664. doi:10.1016/S0002-9149(77)80125-2
   PubMed Web of Science ®Google Scholar
• Mesquita ET, Jorge AJL, Souza CV, Andrade TR. Cardiac Amyloidosis and its New Clinical Phenotype: heart Failure with Preserved Ejection Fraction. Arq Bras Cardiol. 2017;109(1):71–80.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212. doi:10.1161/CIRCULATIONAHA.108.843334
   PubMed Web of Science ®Google Scholar
• Rubin J, Steidley DE, Carlsson M, Ong M-L, Maurer* MS. Myocardial Contraction Fraction by M-Mode Echocardiography is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. J Card Fail. 2018;24(8):504–511. doi:10.1016/j.cardfail.2018.07.001
   PubMed Web of Science ®Google Scholar
• Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid Int J Exp Clin Investig off J Int Soc Amyloidosis. 2015;22(1):61–66.
   PubMed Web of Science ®Google Scholar
• Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart Br Card Soc. 2012;98(19):1442–1448.
   PubMed Web of Science ®Google Scholar
• Liu D, Hu K, Niemann M, et al. Impact of Regional Left Ventricular Function on Outcome for Patients with AL Amyloidosis. PLoS One. 2013;8(3):e56923. doi:10.1371/journal.pone.0056923
   PubMed Web of Science ®Google Scholar
• Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(6):1066–1072. doi:10.1161/CIRCIMAGING.113.000683
   PubMed Web of Science ®Google Scholar
• Tuzovic M, Yang EH, Baas AS, et al. Cardiac Amyloidosis: diagnosis and Treatment Strategies. Curr Oncol Rep. 2017;19(7):46. doi:10.1007/s11912-017-0607-4
   PubMed Web of Science ®Google Scholar
• Barros-Gomes S, Williams B, Nhola LF, et al. Prognosis of Light Chain Amyloidosis With Preserved LVEF: added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC Cardiovasc Imaging. 2017;10(4):398–407. doi:10.1016/j.jcmg.2016.04.008
   PubMed Web of Science ®Google Scholar
• Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017;18(9):1057–1064. doi:10.1093/ehjci/jew298
   PubMed Web of Science ®Google Scholar
• Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012;60(12):1067–1076. doi:10.1016/j.jacc.2012.04.043
   PubMed Web of Science ®Google Scholar
• Korosoglou G, Giusca S, Gitsioudis G, Erbel C, Katus HA. Cardiac magnetic resonance and computed tomography angiography for clinical imaging of stable coronary artery disease. Diagnostic classification and risk stratification. Front Physiol. 2014;5:291. doi:10.3389/fphys.2014.00291
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466–477. doi:10.1016/j.jacc.2017.05.053
   PubMed Web of Science ®Google Scholar
• Bhatti S, Watts E, Syed F, et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016;17(9):970–977. doi:10.1093/ehjci/jew101
   PubMed Web of Science ®Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–193. doi:10.1161/01.CIR.0000152819.97857.9D
   PubMed Web of Science ®Google Scholar
• Boynton SJ, Geske JB, Dispenzieri A, et al. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–686. doi:10.1016/j.jcmg.2015.10.027
   PubMed Web of Science ®Google Scholar
• Minutoli F, Di Bella G, Mazzeo A, et al. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol. 2013;200(3):W256–265. doi:10.2214/AJR.12.8737
   PubMed Web of Science ®Google Scholar
• Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570–1579. doi:10.1161/CIRCULATIONAHA.115.016567
   PubMed Web of Science ®Google Scholar
• Austin BA, Tang WHW, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2(12):1369–1377. doi:10.1016/j.jcmg.2009.08.008
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–164. doi:10.1016/j.jcmg.2009.09.023
   PubMed Web of Science ®Google Scholar
• Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019;6(5):1041–1051. doi:10.1002/ehf2.12511
   PubMed Web of Science ®Google Scholar
• Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–142. doi:10.1016/j.jcmg.2013.08.015
   PubMed Web of Science ®Google Scholar
• Kristen AV, Aus Dem Siepen F, Scherer K, et al. Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid Int J Exp Clin Investig off J Int Soc Amyloidosis. 2015;22(2):132–141.
   PubMed Web of Science ®Google Scholar
• Chatzantonis G, Bietenbeck M, Elsanhoury A, et al. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol off J Ger Card Soc. 2021;110(4):555–568. doi:10.1007/s00392-020-01771-1
   PubMed Web of Science ®Google Scholar
• Dass S, Suttie JJ, Piechnik SK, et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(6):726–733. doi:10.1161/CIRCIMAGING.112.976738
   PubMed Web of Science ®Google Scholar
• Hosch W, Bock M, Libicher M, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol. 2007;42(9):636–642. doi:10.1097/RLI.0b013e318059e021
   PubMed Web of Science ®Google Scholar
• Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–165. doi:10.1016/j.jcmg.2013.10.008
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–497. doi:10.1016/j.jcmg.2012.11.013
   PubMed Web of Science ®Google Scholar
• Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392–398. doi:10.1161/CIRCIMAGING.112.000070
   PubMed Web of Science ®Google Scholar
• Wang TKM, Brizneda MV, Kwon DH, et al. Reference Ranges, Diagnostic and Prognostic Utility of Native T1 Mapping and Extracellular Volume for Cardiac Amyloidosis: a Meta-Analysis. J Magn Reson Imaging JMRI. 2020;2:548.
   Google Scholar
• Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: a Meta-Analysis. JACC Cardiovasc Imaging. 2020;13(6):1299–1310. doi:10.1016/j.jcmg.2020.03.010
   PubMed Web of Science ®Google Scholar
• Vo HQ, Marwick TH, Negishi K. Pooled summary of native T1 value and extracellular volume with MOLLI variant sequences in normal subjects and patients with cardiovascular disease. Int J Cardiovasc Imaging. 2020;36(2):325–336. doi:10.1007/s10554-019-01717-3
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson off J Soc Cardiovasc Magn Reson. 2017;19(1):75.
   PubMedGoogle Scholar
• Mongeon F-P, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5(9):897–907. doi:10.1016/j.jcmg.2012.04.006
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–819. doi:10.1016/j.jcmg.2018.02.006
   PubMed Web of Science ®Google Scholar
• Brahmanandam V, McGraw S, Mirza O, Desai AA, Farzaneh-Far A. Regression of cardiac amyloidosis after stem cell transplantation assessed by cardiovascular magnetic resonance imaging. Circulation. 2014;129(22):2326–2328. doi:10.1161/CIRCULATIONAHA.114.009135
   PubMed Web of Science ®Google Scholar
• Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2021;14(1):189–199. doi:10.1016/j.jcmg.2020.07.043
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–39. doi:10.1161/CIRCIMAGING.112.978627
   PubMed Web of Science ®Google Scholar
• Duca F, Kammerlander AA, Panzenböck A, et al. Cardiac Magnetic Resonance T1 Mapping in Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2018;11(12):1924–1926. doi:10.1016/j.jcmg.2018.06.010
   PubMed Web of Science ®Google Scholar
• Scully PR, Patel KP, Saberwal B, et al. Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients. JACC Cardiovasc Imaging. 2020;13(10):2177–2189. doi:10.1016/j.jcmg.2020.05.029
   PubMed Web of Science ®Google Scholar
• Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1493 consecutive patients: assessment of myocardial wall motion and perfusion. J Am Coll Cardiol. 2010;56(15):1225–1234. doi:10.1016/j.jacc.2010.06.020
   PubMed Web of Science ®Google Scholar
• Korosoglou G, Giusca S, Hofmann NP, et al. Strain-encoded magnetic resonance: a method for the assessment of myocardial deformation. ESC Heart Fail. 2019;6(4):584–602. doi:10.1002/ehf2.12442
   PubMed Web of Science ®Google Scholar
• Korosoglou G, Giusca S, Montenbruck M, et al. Fast Strain-Encoded Cardiac Magnetic Resonance for Diagnostic Classification and Risk Stratification of Heart Failure Patients. JACC Cardiovasc Imaging. 2021;14(6):1177–1188. doi:10.1016/j.jcmg.2020.10.024
   PubMed Web of Science ®Google Scholar
• Giusca S, Steen H, Montenbruck M, et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23(1):92. doi:10.1186/s12968-021-00775-8
   PubMed Web of Science ®Google Scholar
• Bravo PE, Fujikura K, Kijewski MF, et al. Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits. JACC Cardiovasc Imaging. 2019;12(7Part 1):1165–1173. doi:10.1016/j.jcmg.2018.06.016
   PubMedGoogle Scholar
• Williams LK, Forero JF, Popovic ZB, et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson off J Soc Cardiovasc Magn Reson. 2017;19(1):61.
   PubMedGoogle Scholar
• Oda S, Utsunomiya D, Nakaura T, et al. Identification and Assessment of Cardiac Amyloidosis by Myocardial Strain Analysis of Cardiac Magnetic Resonance Imaging. Circ J Off J Jpn Circ Soc. 2017;81(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Aljaroudi WA, Desai MY, Tang WHW, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol off Publ Am Soc Nucl Cardiol. 2014;21(2):271–283.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084. doi:10.1016/j.jacc.2005.05.073
   PubMed Web of Science ®Google Scholar
• Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. 99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17–24. doi:10.3109/03009734.2015.1122687
   PubMed Web of Science ®Google Scholar
• Musumeci MB, Cappelli F, Russo D, et al. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1314–1321. doi:10.1016/j.jcmg.2019.10.015
   PubMed Web of Science ®Google Scholar
• Chang ICY, Bois JP, Bois MC, Maleszewski JJ, Johnson GB, Grogan M. Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2018;11(1):e007059. doi:10.1161/CIRCIMAGING.117.007059
   PubMed Web of Science ®Google Scholar
• Poterucha TJ, Elias P, Ruberg FL, et al. False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. JACC Cardiovasc Imaging. 2021;14:2042.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–670. doi:10.1016/j.jcmg.2011.03.016
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470–478. doi:10.1007/s00259-010-1642-7
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612
   PubMed Web of Science ®Google Scholar
• Van Der Gucht A, Cottereau A-S, Abulizi M, et al. Apical sparing pattern of left ventricular myocardial 99mTc-HMDP uptake in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol off Publ Am Soc Nucl Cardiol. 2018;25(6):2072–2079.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201. doi:10.1161/CIRCIMAGING.112.000132
   PubMed Web of Science ®Google Scholar
• Castano A, Haq M, Narotsky DL, et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1(8):880–889. doi:10.1001/jamacardio.2016.2839
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Tower-Rader A, et al. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):234–242. doi:10.1016/j.jcmg.2017.06.020
   PubMed Web of Science ®Google Scholar
• Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–1662. doi:10.1007/s00259-014-2787-6
   PubMed Web of Science ®Google Scholar
• Lee S-P, Lee ES, Choi H, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8(1):50–59. doi:10.1016/j.jcmg.2014.09.018
   PubMed Web of Science ®Google Scholar
• Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905–1908. doi:10.1093/eurheartj/ehx047
   PubMed Web of Science ®Google Scholar
• Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68(10):1014–1020. doi:10.1016/j.jacc.2016.06.033
   PubMed Web of Science ®Google Scholar